Medical consensus proposes renaming PCOS to PMOS

An international medical consensus published in The Lancet has proposed renaming Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to more accurately reflect the complexity of the condition, which involves multiple endocrine and metabolic systems rather than being limited to the ovaries.

Affecting approximately one in eight women, PMOS is a lifelong condition. While often associated with fertility issues, it also impacts insulin sensitivity, metabolism, skin, hair, and cardiovascular health. Experts emphasize that the condition does not disappear after a woman's reproductive years; metabolic risks such as insulin resistance, blood pressure, and cholesterol levels may persist even if menstrual cycles become more regular.

Common symptoms include irregular menstruation, acne, hirsutism, hair thinning, weight changes, and difficulty conceiving. Medical professionals urge women not to normalize these symptoms and advocate for early detection to better manage long-term reproductive and metabolic implications.